Adaptive Biotechnologies Corp (NASDAQ: ADPT) saw its stock surge 5.98% in after-hours trading on Thursday following the release of its first-quarter 2025 financial results, which significantly outperformed analysts' expectations.

The biotechnology company reported a quarterly loss of $0.20 per share, beating the analyst consensus estimate of $0.31 by 35.48%. This marks a substantial improvement from the $0.33 per share loss reported in the same quarter last year. Revenue for the quarter came in at $52.44 million, surpassing the analyst estimate of $42.7 million by 22.77% and representing a 25.14% increase from the $41.87 million reported in the prior-year period.

Adaptive Biotechnologies' financial performance showed notable improvements across several metrics. The company's net loss for Q1 was $29.83 million, considerably better than the expected $45 million loss. Operating loss also beat estimates, coming in at $29.604 million compared to the anticipated $43.7 million. These results, coupled with the company's forward-looking guidance, including expected full-year revenue for its MRD (Minimal Residual Disease) business between $180 million and $190 million, appear to have boosted investor confidence in Adaptive Biotechnologies' growth trajectory and financial health.